Abstract
Immobilization of proteins has been examined to improve implant surfaces. In this study, titanium surfaces were modified with nanofunctionalized denosumab (cDMAB), a human monoclonal anti-RANKL IgG. Noncoding DNA oligonucleotides (ODN) served as linker molecules between titanium and DMAB. Binding and release experiments demonstrated a high binding capacity of cDMAB and continuous release. Human peripheral mononuclear blood cells (PBMCs) were cultured in the presence of RANKL/MCSF for 28 days and differentiated into osteoclasts. Adding soluble DMAB to the medium inhibited osteoclast differentiation. On nanofunctionalized titanium specimens, the osteoclast-specific TRAP5b protein was monitored and showed a significantly decreased amount on cDMAB-titanium in PBMCs + RANKL/MCSF. PBMCs on cDMAB-titanium also changed SEM cell morphology. In conclusion, the results indicate that cDMAB reduces osteoclast formation and has the potential to reduce osteoclastogenesis on titanium surfaces.
Original language | English |
---|---|
Article number | 1002 |
Number of pages | 12 |
Journal | International journal of molecular sciences |
Volume | 20 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 Mar 2019 |
Externally published | Yes |
Keywords
- Cell Differentiation/drug effects
- Denosumab/pharmacology
- Humans
- Macrophage Colony-Stimulating Factor/pharmacology
- Male
- Monocytes/cytology
- Nanoparticles/chemistry
- Osteogenesis/drug effects
- RANK Ligand/pharmacology
- Solubility
- Tartrate-Resistant Acid Phosphatase/metabolism
- Titanium/pharmacology
- RANKL
- titanium
- OPG
- IMPLANTS
- implant
- WEAR
- LIGAND
- denosumab
- RANKL/RANK/OPG SYSTEM
- MODEL
- ALENDRONATE
- PERIPROSTHETIC OSTEOLYSIS
- osteoclast
- nanofunctionalization